Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies

Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies

An increasing healthcare challenge in the management of haematological malignancy (HM) is secondary immunodeficiency. From January 2019, the EMA included the evaluation of specific antibody (Ab) responses to better select patients for immunoglobulin replacement therapy (IgRT). We evaluated Ab respon...

Full description

Saved in:
Bibliographic Details
Published in:Clinical immunology (Orlando, Fla.) Vol. 210; p. 108307
Main Authors: Ochoa-Grullón, J., Benavente Cuesta, C., Pérez López, C., Peña Cortijo, A., Rodríguez de la Peña, A., Álvarez Carmona, A., Mateo Morales, M., Llano-Hernández, K., Williams, L.J., Rodríguez de Frías, E., Guevara-Hoyer, K., Cordero Torres, G., Orte, C., Fernández-Arquero, M., Fernández-Paredes, L., Serrano-García, I., Recio, M.J., Pérez de Diego, R., Martínez, R., Sánchez-Ramón, S.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01-01-2020
Subjects:
Haematological malignancies
Hypogammaglobulinemia
Pneumo23
Specific polysaccharide ab response
Typhim vi
IgRT
TV
Specific polysaccharide ab response
HM
PPV
Pneumo23
Hypogammaglobulinemia
HC
Haematological malignancies
Typhim vi
SID
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An increasing healthcare challenge in the management of haematological malignancy (HM) is secondary immunodeficiency. From January 2019, the EMA included the evaluation of specific antibody (Ab) responses to better select patients for immunoglobulin replacement therapy (IgRT). We evaluated Ab responses to pneumococcal and Salmonella typhi pure polysaccharide immunization in a cohort of 42 HM patients and 24 healthy-controls. Pre-post specific Ab concentrations were measured by ELISA at 4 weeks. Globally, significantly lower Typhim Vi (TV) seroprevalence (9%) compared to 23-valent pneumococcal polysaccharide vaccine (PPV) (76%) (p <0.001) was observed. TV non responders (88%) were higher than PPV non responders (62%) (p <0.0001) and correlated better to infectious history. By ROC analysis, pre-post 5-fold TV increase was the best cut-off to discriminate HM with recurrent infections and controls (sensitivity 91%, specificity 100%). Despite the small sample cohort, our results suggest that specific anti-S typhi Ab response is a useful complementary assay in the diagnosis and management decision of SID to HM.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1521-6616
1521-7035
DOI:10.1016/j.clim.2019.108307